RNA Therapeutics: From Concept to Clinic

Phillip D. Zamore, Ph.D. has been an Investigator of the Howard Hughes Medical Institute since 2008. In 2016, he became the Chair of the RNA Therapeutics Institute, which was established at the University of Massachusetts Medical School in 2009. Dr. Zamore also is Professor of Biochemistry and Molecular Pharmacology, the department he joined in 1999, and he became the Gretchen Stone Cook Professor of Biomedical Sciences in 2005. Dr. Zamore received his A.B. (1986) and Ph.D. (1992) degrees in Biochemistry and Molecular Biology from Harvard University. He then pursued postdoctoral studies on the role of the RNA binding proteins in Drosophila development at The Whitehead Institute for Biomedical Research, in Cambridge, Massachusetts. 

Dr. Zamore’s laboratory studies small RNA silencing pathways in eukaryotes and prokaryotes, including RNA interference (RNAi), microRNA, and PIWI-interacting RNA pathways.  Dr. Zamore and his collaborators seek to use these insights to design therapies for human diseases, including Huntington’s disease. Under Dr. Zamore’s mentorship, the Zamore Lab has produced dozens of researchers working at top institutions both in the United States and abroad. 

In 2015, Dr. Zamore was awarded the Chancellor’s Medal for Excellence in Scholarship at the University of Massachusetts Medical School. In 2023, Dr. Zamore was elected as a member to both the American Academy of Arts and Sciences and the National Academy of Sciences. 

To date, Dr. Zamore has more than 170 publications and has been among the most highly cited researchers for more than a decade. He serves on the editorial boards of numerous journals and is in demand as a presenter at conferences and institutions worldwide. 

Dr. Zamore holds more than 20 patents, with other applications pending; he was elected a Fellow of the National Academy of Inventors in 2014. In 2002, Dr. Zamore co-founded Alnylam Pharmaceuticals (Cambridge, MA), a publicly traded biotech company which now has more than 1000 employees and multiple drugs in clinical trials. Alnylam’s first drug, ONPATTRO, a first-of-its-kind RNAi therapeutic, for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults, was approved by the FDA in 2018. In 2014, he co-founded Voyager Therapeutics in Cambridge, MA. He serves on the scientific advisory boards of Alnylam, Voyager, and ProQR.

Kim graduated from Seoul National University in 1992 and received her Ph.D. in 1998 from the University of Oxford where she studied lentiviruses and gene delivery. For postdoctoral training, she joined the Gideon Dreyfuss lab at the University of Pennsylvania to study mRNA surveillance. Kim moved back to Seoul National University in 2001 to set up her own group and has been investigating how genes are regulated at the RNA level.

The Kim lab delineated the microRNA pathway, identified key factors including DROSHA, and revealed their action mechanisms and structures. Her group also uncovered the roles of noncanonical RNA tailing such as uridylation and mixed tailing in the control of microRNAs, mRNAs, and viral RNAs. She is a recipient of the L’Oreal-UNESCO Women in Science Award, the Hoam Prize, and the Asan Prize; was elected members of KAS, NAS, EMBO, and the Royal Society; and serves on the editorial boards of Science, Cell, Molecular Cell, GD, and EMBO J.

Phillip D. Zamore, Ph.D. has been an Investigator of the Howard Hughes Medical Institute since 2008. In 2016, he became the Chair of the RNA Therapeutics Institute, which was established at the University of Massachusetts Medical School in 2009. Dr. Zamore also is Professor of Biochemistry and Molecular Pharmacology, the department he joined in 1999, and he became the Gretchen Stone Cook Professor of Biomedical Sciences in 2005. Dr. Zamore received his A.B. (1986) and Ph.D. (1992) degrees in Biochemistry and Molecular Biology from Harvard University. He then pursued postdoctoral studies on the role of the RNA binding proteins in Drosophila development at The Whitehead Institute for Biomedical Research, in Cambridge, Massachusetts. 

Dr. Zamore’s laboratory studies small RNA silencing pathways in eukaryotes and prokaryotes, including RNA interference (RNAi), microRNA, and PIWI-interacting RNA pathways.  Dr. Zamore and his collaborators seek to use these insights to design therapies for human diseases, including Huntington’s disease. Under Dr. Zamore’s mentorship, the Zamore Lab has produced dozens of researchers working at top institutions both in the United States and abroad. 

In 2015, Dr. Zamore was awarded the Chancellor’s Medal for Excellence in Scholarship at the University of Massachusetts Medical School. In 2023, Dr. Zamore was elected as a member to both the American Academy of Arts and Sciences and the National Academy of Sciences. 

To date, Dr. Zamore has more than 170 publications and has been among the most highly cited researchers for more than a decade. He serves on the editorial boards of numerous journals and is in demand as a presenter at conferences and institutions worldwide. 

Dr. Zamore holds more than 20 patents, with other applications pending; he was elected a Fellow of the National Academy of Inventors in 2014. In 2002, Dr. Zamore co-founded Alnylam Pharmaceuticals (Cambridge, MA), a publicly traded biotech company which now has more than 1000 employees and multiple drugs in clinical trials. Alnylam’s first drug, ONPATTRO, a first-of-its-kind RNAi therapeutic, for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults, was approved by the FDA in 2018. In 2014, he co-founded Voyager Therapeutics in Cambridge, MA. He serves on the scientific advisory boards of Alnylam, Voyager, and ProQR.

Victor Ambros earned his undergraduate degree in 1975, his doctorate in 1979 and completed his postdoctoral fellowship in 1983, all at the Massachusetts Institute of Technology. During graduate school, he worked with David Baltimore, PhD, a co-recipient of the 1975 Nobel Prize in Physiology or Medicine for discoveries related to the interaction between tumor viruses and genetic material of the cell. In Dr. Baltimore’s lab, Ambros studied the poliovirus genome structure and replication. Ambros then conducted his postdoctoral research in the lab of H. Robert Horvitz, who shared the 2002 Nobel Prize in Physiology or Medicine for his research related to genetic regulation of organ development and programmed cell death. Ambros’ research in Dr. Horvitz’s lab focused on genetic pathways that directed the developmental timing in C. elegans. After Ambros completed his fellowship, he continued his research as a faculty member at Harvard University (1984-1992), Dartmouth College and Dartmouth Medical School (1992-2008), and the University of Massachusetts Chan Medical School (2008-present).

Ambros was elected to the National Academy of Sciences in 2007 and the American Academy of Arts & Sciences in 2011. He has received numerous honors for his scientific achievements including the Lasker Award and the Gairdner Foundation International Award in 2008; the Dr. Paul Janssen Award for Biomedical Research in 2012; the Keio Medical Science Award in 2013; the Wolf Prize, Gruber Genetics Prize and Breakthrough Prize in Life Sciences (shared) in 2014; and the Prize in Developmental Biology from the March of Dimes (shared) in 2016. Ambros was awarded the 2024 Nobel Prize for Physiology or Medicine for his co-discovery of microRNA, short single-stranded RNA molecules that are now understood to play critical roles in post-transcriptional gene regulation.

In 2008, H. Scott Silverman and his father Jeffrey L. Silverman endowed the Silverman Chair in Natural Sciences at the University of Massachusetts Chan Medical School to honor Ambros. The endowment symbolizes the Silvermans’ enthusiasm for Ambros’ work and comes from a longtime friendship formed in 1997 when the younger Silverman completed his honors research thesis under Ambros’ guidance at Dartmouth College.

Luisa Cochella grew up in Buenos Aires, Argentina. She obtained her Licenciatura (B.S.-Masters equivalent) in Biology from the Universidad de Buenos Aires and her PhD from Johns Hopkins University in Baltimore, where she conducted her thesis work in the lab of Dr. Rachel Green. For her postdoc, Luisa moved from studying fundamental aspects of protein synthesis, to using the worm C. elegans as a genetic system to study cell differentiation and development in the lab of Dr. Oliver Hobert at Columbia University in New York. Combining these two diverse trainings, Luisa started her independent group at the IMP in Vienna, Austria in 2013, with the goal to understand the basic gene regulatory mechanisms that drive the development of a multicellular organism. In 2021 the Cochella lab moved to Johns Hopkins School of Medicine, Department of Molecular Biology and Genetics. A large part of the Cochella lab focuses on the functions of microRNAs in animal development.

Luisa has been awarded an ERC Starting Grant, an NSF Career Award, she was an EMBO Young Investigator and was awarded the Elisa Izaurralde Award from the RNA Society in 2022.

Dr. Alisha ‘Jonesy’ Jones, one of C&EN News 2024 Talented Twelve, is a James Weldon Johnson Assistant Professor of Chemistry at New York University in the Department of Chemistry. Jonesy was a postdoctoral researcher in the lab of Dr. Michael Sattler in Munich, Germany, and earned her PhD in Chemistry in the lab of Dr. Gabriele Varani at the University of Washington.

Research in the Jones Lab focuses on investigating the structural dynamics of long noncoding RNAs (lncRNAs) and how they are linked to specific biological processes. Her team deploys a combination of biophysical, biochemical, and computational techniques to study how lncRNAs transition between various structured states and how they interact with other biomolecules. Considering that lncRNAs are critical regulators of gene expression, her lab’s work has the potential to increase overall knowledge regarding lncRNA structure-function relationships, and offers a starting point for therapeutically targeting lncRNAs when they are implicated in a disease.

Wendy previously completed her B.Sc. and M.Sc. in Biochemistry at the University of Toronto, where her master’s thesis work in the lab of Dr. Angus McQuibban, centered on how coordination of mitophagy and mitochondrial biogenesis affects cellular health and Parkinson’s disease. Her Ph.D. thesis work in the Mello lab focuses on characterizing currently undescribed mechanisms of the C. elegans piRNA pathway, including Mutator component-independent silencing and PRG-1 slicer function.

Disha research focuses on engineering next-generation antisense oligonucleotide (ASO) therapeutics for enhanced potency and precise subcellular targeting. She has developed novel ASO conjugates that improve nuclear import and exploit lysosomal trafficking for mRNA knockdown. Disha’s work bridges organic synthesis, molecular biology, and nucleic acidchemistry to develop new therapeutic strategies in molecular medicine.

UMass Boston graduate Michael Spellberg, Ph.D.,is a registered patent attorney practicing in the area of biotechnology. Mike’s practice includes biologic therapies, research tools, screening assays, bioprocessing and purification, with a particular focus on oligonucleotide therapeutics,mRNA technology, antibody therapeutics, and cell therapies. Mike’s research background is in cancer immunology and molecular biology. Prior to joining Lathrop GPM, Mike served as a postdoctoral research fellow for Dr. Carl Novina at the DanaFarber Cancer Institute, where he used cutting-edge CRISPR technology in the development of tools to epigenetically modify cancer cells and immune cells as a novel therapy. Mike received his Ph.D. at Brandeis University in the lab of Dr. Michael Marr. During this time,he identified a novel function of a transcription factor for its role in regulating the small RNA pathways and viral immunity.

Athma Pai is an RNA systems geneticist working at the interface of RNA biology, functional genomics, and computational biology. Athma received her Ph.D. in Human Genetics from the University of Chicago, completed a Jane Coffin Childs postdoctoral fellowship in the Department of Biology at MIT, and assumed her current position as an Assistant Professor in the RNA Therapeutics Institute at the University of Massachusetts Chan Medical School in January 2018. Her lab works on developing and applying methods to study the kinetics of RNA processing and understanding how various steps in RNA maturation are efficiently coordinated through the lifecycle of an RNA molecule. Her work has been recognized with professional awards and grants such as the NIH Maximizing Investigators Research Award, NSF CAREER Award, and the UMass Chan Early Career Achievement in Science and Health Award.

Prior to this Richard was the Department of Pediatrics Stem Cell Biology Chair in the Division of Hematology/Oncology at Boston Children’s Hospital, Professor in the Department of Biological Chemistry and Molecular Pharmacology, at Harvard Medical School (HMS), and Co-Director, of the HMS Initiative for RNA Medicine. He received a Ph.D. from Cambridge University for his research performed at the Babraham Institute. He did postdoctoral work at the Fox Chase Cancer Center and the Wistar Institute, Philadelphia. His research focuses on understanding molecular and cellular mechanisms of RNA regulation and the relevance of these pathways in stem cell biology, development, and human diseases including cancer. Most recently, his lab has been focused on the role of RNA modifications – the epitranscriptome, in cancer biology. Notably, they identified oncogenic roles for the mRNA methyltransferase (MTase) METTL3 and the tRNA MTase METTL1 in numerous cancer types. Their work is supported by an outstanding investigator award from the National Cancer Institute.

Scientific accomplishments have been published broadly in major journals, such as Nature, Cell and Science, and include pioneering studies that:

• Revealed molecular and cellular mechanisms of microRNA biogenesis;
• Discovered novel RNA quality control and decay pathways;  
• Identified the RNA methyltransferases METTL1 and METTL3 as oncogenes and new targets for cancer therapies; and
• Linked changes to the ‘epitranscriptome’ with translational reprogramming in cancer.  

Ryan is a New Jersey native who completed his undergraduate training at MIT, where he worked in the lab of Phillip Sharp. Subsequently he moved to Stanford where he completed his M.D. and Ph.D. with Howard Chang. As a post-doc he changed fields to learn both chemistry and glycobiology with Carolyn Bertozzi at Stanford. In 2021, the Flynn Lab opened at Boston Children’s Hospital in the Stem Cell Program and the Department of Stem Cell and Regenerative Biology at Harvard University. The Flynn Lab is currently focused on advancing methods, mechanisms, and functions surrounding the glycoRNA molecule, which operates at the interface of RNA biology and the cell surface.

Grace Lee is conducting research in the lab of Dr. Colin Conine. Her work focuses on how small RNAs regulate gene expression during early development, with a particular interest in sperm - derived microRNAs and their role in shaping embryonic gene regulation. Grace integrates molecular biology and high- throughput sequencing approaches to uncover mechanisms of epigenetic inheritance in mammals. Upon completion of her  graduate studies, she plans to pursue postdoctoral research in  RNA therapeutics, with a focus on developing and optimizing RNA delivery systems to enable targeted and effected treatments.

Dr. Hailing Jin is a Cy Mouradick Chair Professor in the Department of Microbiology & Plant Pathology at the University of California, Riverside, USA. Her research focuses on the roles of RNAs, epigenetics, and antimicrobial peptides in plant-microbe interactions, with the aim of developing innovative and eco-friendly strategies for crop protection against fungal and bacterial pathogens. Her lab discovered cross-kingdom RNA communication between plants and pathogens. They have also demonstrated the crucial role of extracellular vesicles in this process. Additionally, her lab found that many fungal pathogens can efficiently take up RNAs and vesicles from the environment, providing the essential basis for the development of spray-induced gene silencing techniques for crop protection.

Dr. Jin earned her PhD from the Shanghai Institute of Plant Physiology & Ecology, Chinese Academy of Sciences, and completed her postdoctoral training at the John Innes Centre, UK and the University of California, Berkeley. She has published a total of 115 peer-reviewed papers and has an H-index of 65. Dr. Jin is a Senior Member of the National Academy of Inventors (NAI), a Fellow of the American Association for the Advancement of Science (AAAS), a Fellow of the American Academy of Microbiology (AAM), a Fellow of the American Phytopathological Society (APS), and a CIFAR Fellow of the Canadian Institute for Advanced Research. She was recognized as a Highly Cited Researcher by Web of Science. She was recently elected to National Academy of Sciences (NAS) in 2025.

Marc Friedländer undertook his undergraduate studies in bioinformatics at the University Copenhagen under the supervision of Anders Krogh and his PhD in Berlin under the supervision of Nikolaus Rajewsky - developing the miRDeep algorithm. As a PI and tenured associate professor, he has established the Quantitative RNA Biology lab at SciLifeLab/Stockholm University.

The group has recently developed agoTRIBE - the first method to experimentally map microRNA targets transcriptome-wide in single cells - and has discovered and profiled RNA fragments in historical and ancient animals, including the extinct Tasmanian tiger.

Luca is an RNA biologist specializing in developing innovative experimental and computational methods to elucidate how RNA and proteins interact to regulate diverse aspects of cell biology. His research leverages cutting-edge approaches to uncover the molecular mechanisms by which RNA-binding proteins and long non-coding RNAs (lncRNAs) influence tissue homeostasis, with a particular focus on their roles in disease processes such as cancer and autoimmune disorders.

Currently, in Paul Khavari’s laboratories, Luca investigates how RNA-binding proteins and lncRNAs modulate gene expression and cellular responses, aiming to identify new regulatory pathways and potentially new therapeutic targets. His work contributes to the lab’s broader mission of understanding genome regulation and innovating genetic models to study human health and disease, especially in the context of epithelial biology.

More Info: https://profiles.stanford.edu/luca-ducoli?tab=bio

Ariane (she/her) holds a Master of Science in Developmental Biology and Genetics from the University of Vienna in Austria. During her studies, she gained practical experience in next-generation sequencing (NGS) technologies at the VBC. Ariane joined Luisa Cochella’s laboratory at the IMP (Vienna, Austria) for her doctoral studies. In 2021, she relocated with the laboratory to the Johns Hopkins School of Medicine in Baltimore, USA. Her current research focuses on the functions of microRNAs in maintaining cellular homeostasis within mammalian cells and elucidating their mechanisms of action.

Dr. He Zang is the cofounder and CTO of Raina Biosciences, an MIT spinout advancing mRNA drug development through generative AI and synthetic biology. Dr. Zhang received his Ph.D. in Computer Science from Oregon State University and began his career at Baidu Research (Silicon Valley), where he worked as a Research Scientist and later served as tech lead of the computational biology team. His contributions include the development of linear-time RNA secondary structure prediction algorithms that improve both computational efficiency and predictive accuracy. His research has been published in leading venues such as PNAS, Nucleic Acids Research (NAR), and ISMB. Dr. Zhang is also the first author of the Linear Design algorithm, published in Nature , which represents a major advancement in AI-driven mRNA design by enhancing vaccine stability and immunogenicity.

Daniel J. Siegwart holds the W. Ray Wallace Distinguished Chair in Molecular Oncology Research and serves as the Director of the Program in Genetic Drug Engineering, Director of the Drug Delivery Program in Biomedical Engineering, and Co-leader of the Chemistry and Cancer Program in the NCI-designated SCCC. He received a B.S. in Biochemistry from Lehigh University (2003), and a Ph.D. in Chemistry from Carnegie Mellon University (2008), studying with Professor Krzysztof Matyjaszewski.

He also studied as an NSF EAPSI Research Fellow at the University of Tokyo with Professor Kazunori Kataoka (2006). He then completed an NIH NSRA Postdoctoral Fellowship at MIT with Professor Robert Langer (2008-2012). He has received awards including a CPRIT Scholar Award, an American Cancer Society Research Scholar Award, the Young Innovator Award in Nanobiotechnology, Biomaterials Science Emerging Investigator Award, and election to the Controlled Release Society (CRS) College of Fellows and the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows. His research laboratory utilizes materials chemistry to enable targeted nanoparticle delivery of genomic medicines.

Their efforts led to an understanding of the essential physical and chemical properties of synthetic carriers required for therapeutic delivery of siRNA, miRNA, tRNA, pDNA, mRNA, and gene editors. His lab has been at the forefront in the design of synthetic carriers for gene editing and has applied these technologies for correction of genetic diseases and treatment of cancer. They reported the first non-viral system for in vivo CRISPR/Cas gene editing. They developed Selective ORgan Targeting (SORT) lipid nanoparticles (LNPs), which was the first strategy for predictable tissue specific mRNA delivery and gene editing. They ultimately aspire to utilize chemistry and engineering to make a beneficial impact on human health.

Dr. Daniel earned his PhD at UNC Chapel Hill and completed postdoctoral training with Dr. Chris Burge at MIT. His research focuses on RNA biology and gene regulation, particularly in the context of cancer and neurodegenerative disease. The Dominguez Lab investigates the molecular mechanisms of RNA-protein interactions and their regulatory consequences, using a multidisciplinary approach that combines computational biology, molecular biology, high-throughput biochemical assays, and animal models.

Previous work has included developing nuanced models of RNA-binding protein (RBP) specificity, examining the functional impact of RBP mutations, exploring the evolution of RNA-protein interactions, and uncovering mechanisms of alternative splicing in cancer and cell cycle regulation. The lab’s research is supported by the National Cancer Institute (NCI), the National Institute of General Medical Sciences (NIGMS), and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Dr. Wen research centers on mirror-image nucleic acids—synthetic L-RNA and L-DNA—as a novel class of RNA-based therapeutics with enhanced enzymatic stability, structural tunability, and non-immunogenic properties. His lab develops L-RNA aptamers and L-nucleic acid nanostructures for targeted drug delivery and gene regulation, with a particular focus on applications in cancer treatment. In addition to therapeutic development, his team explores nucleic acid chemistry, aptamer selection via mirror-image SELEX, and RNA–protein structural interactions using computational tools. His lab integrates nanotechnology, synthetic biology, and structural biology to engineer nucleic acid-based platforms to advance RNA therapeutics beyond current limitations in stability, targeting, and delivery.

Raghu Kalluri is a CPRIT Established Investigator and holds the Frederick F. Becker Distinguished University Chair of Cancer Research. Dr. Kalluri’s research program is focused on innovative research to unravel how cells and their environment communicate to maintain organ health, and how such communication networks are altered in cancer and other diseases. Current areas of research in the laboratory include cancer biology and metastasis, tumor microenvironment, tissue injury and regeneration, aging, and the biology of exosomes in health and disease.

Dr. Kalluri's research is translationally focused, with an implicit mission to develop new strategies for diagnosis and therapy. To date, his discoveries have been translated into nine successful clinical studies and Phase I clinical trials for kidney diseases, fibrosis and cancer, and led to the creation of six biotechnology companies using intellectual property generated in the Kalluri laboratory. Dr. Kalluri has been recognized for his excellence in research and teaching and the Kalluri laboratory is a fertile training ground for the next generation of scientists and physician-scientists. He has mentored over 300 research trainees during the past three decades and led numerous education and training programs as Director or co-Director at both Harvard and MD Anderson Cancer Center. Training successful researchers is one of Dr. Kalluri’s core commitments for which he takes immense pride.

Dr. Kalluri’s research achievements have been acknowledged in the form of several distinguished awards. He received the 2015 Jacob Henle Medal for Excellence in Medicine and the 2016 Ruth Leff Siegel Award for Excellence in Pancreatic Cancer Research. Kalluri has been funded by the NIH continuously for 29 years and, in 2022, he received the prestigious NCI Outstanding Investigator Award. In 2023, he was conferred with The Dallas/Fort Worth Living Legend Faculty Achievement Award in Basic Research. Dr. Kalluri is a Fellow of the American Society for Clinical Investigation, The American Association for the Advancement of Science, and the Association of American Physicians.

Alexis received her B. S. degree in chemistry from the University of California, Berkeley in December of 2008. She then joined the lab of Jacqueline K. Barton at the California Institute of Technology for her doctoral studies. While at Caltech, she worked as an NSF Graduate Research Fellow on the design, synthesis, and study of DNA mismatch-binding metal complexes and received her Ph.D. in 2014.

She pursued postdoctoral work as a Ruth L. Kirschstein NIH Postdoctoral Fellow in the laboratory of David R. Liu, where she developed base editing. Alexis joined the Department of Chemistry and Biochemistry at the University of California at San Diego in 2017, where her lab develops and applies new precision genome editing techniques to the functional genomics field.

Alexis’s contributions in teaching, mentoring, and research have been recognized through many awards, including the Cottrell Scholar Award, the “Talented 12” recognition by C&EN News, an NSF Faculty Early Career Development (CAREER) award, an NIH early stage investigator Maximizing Investigators’ Research Award (MIRA), and a “40 under 40” recognition in healthcare by Fortune Magazine.

Dr. Genliang work focuses on the application of base, sugar, backbone modification to improve the pharmacology of oligonucleotides acrossmodalities including RNA editing, silencing (ASOand siRNA) and exonskipping. Prior to joining Wave, he worked at Synta and Molecular Insight Pharmaceuticals, contributing to development of several oncology clinical candidates.He earned his Ph.D. in organic chemistry from South Dakota State Universityand conducted postdoctoral research at University of Kansas and Texas A&M University.

Sarah’s expertise is in high throughput screening of small RNAs for therapeutic applications, including CRISPR sgRNAs, prime editing guide RNAs (pegRNAs), tRNAs, as well as engineered and synthetic small RNAs for technology development. She is interested in creative approaches for gene- and mutation-agnostic therapeutic genome editing to expand the reach of these tools to the most patients possible. Sarah did her PhD in Will Greenleaf and Monte Winslow's labs at Stanford working on single cell CRISPR screening and is now doing her postdoc in David Liu's lab at Harvard working on new gene editing approaches.

Dr. Chang research focuses on the structural and mechanistic understanding of RNA-guided systems, including CRISPR-associated transposons and Cas12-family effectors. Using cryo-electron microscopy and biochemical approaches, his lab investigates how these molecular machines recognize and manipulate nucleic acids, with implications for genome editing. Dr. Chang received his Ph.D. from Tsinghua University and conducted postdoctoral research at the Institute of Cancer Research in London and the MRC Laboratory of Molecular Biology in Cambridge, UK.

Xiao holds a B.S. in Biochemistry from Zhejiang University and a Ph.D. in Molecular & Cell Biology from the Chinese Academy of Sciences. She completed postdoctoral fellowships at Harvard University and the University of Pennsylvania. Dr. Wang has published extensively as first, co-first, or senior author in prestigious journals includingThe New England Journal of Medicine,Nature Communications,Nature Genetics,Cell Stem Cell,Journal of the American College of Cardiology, and Circulation. Her research centers on the genetics of cardiovascular and metabolic diseases, identifying genetic factors that contribute to disease onset or prevention and leveraging innovative genome-editing technologies to develop novel therapeutics. Recently, Dr. Wang has focused on applying advanced genome-editing tools to treat inherited genetic disorders. She published significant work as senior author in Nature Communications demonstrating rapid and definitive treatment of phenylketonuria (PKU) in a humanized mouse model. Her current research aims to develop durable, one-time in vivo base and prime editing therapies for inherited diseases such as PKU, pseudoxanthoma elasticum (PXE), and urea cycledisorders.

Disha research focuses on engineering next-generation antisense oligonucleotide (ASO) therapeutics for enhanced potency and precise subcellular targeting. She has developed novel ASO conjugates that improve nuclear import and exploit lysosomal trafficking for mRNA knockdown. Disha’s work bridges organic synthesis, molecular biology, and nucleic acidchemistry to develop new therapeutic strategies in molecular medicine.

UMass Boston graduate Michael Spellberg, Ph.D.,is a registered patent attorney practicing in the area of biotechnology. Mike’s practice includes biologic therapies, research tools, screening assays, bioprocessing and purification, with a particular focus on oligonucleotide therapeutics,mRNA technology, antibody therapeutics, and cell therapies. Mike’s research background is in cancer immunology and molecular biology. Prior to joining Lathrop GPM, Mike served as a postdoctoral research fellow for Dr. Carl Novina at the DanaFarber Cancer Institute, where he used cutting-edge CRISPR technology in the development of tools to epigenetically modify cancer cells and immune cells as a novel therapy. Mike received his Ph.D. at Brandeis University in the lab of Dr. Michael Marr. During this time,he identified a novel function of a transcription factor for its role in regulating the small RNA pathways and viral immunity.

Over the years, Alfica has held multiple leadership positions at CAMP4 therapeutics and Alnylam Pharmaceuticals, spanning from early discovery, new target search, platform biology, improvising delivery, and leading programs to the clinic. Her experience spans rare liver diseases like Alpha-1 antitrypsin deficiency (Belcesiran), Bleeding disorders (Fitusiran); urea cycle disorders; kidney disease, neurodegenerative and neurodevelopment disorders. She graduated from Tata Institute of Fundamental Research (TIFR), Mumbai; received her post-doctoral training at Johns Hopkins and Yale University, studying lipid uptake, cholesterol and oxygen homeostasis in parasites, mammalian cells and mice. She has authored more than 60 articles and patents across various disease areas and technologies.

Dr. Urmila research lies at the intersection of RNA biology, livercancer, metabolic syndrome, and fibrosis. She employs advanced molecular biology techniques, chemicalgenetics, and in vivo preclinical mouse models to investigate disease mechanisms anddevelop RNA-based therapeutics.Her work also explores liver-specificlipidomic changes inmetabolic dysfunction-related fatty liver disease and the effects of binge alcohol consumption on chronic liver injury. 

Dr. Jagtap earned her PhD in Molecular Biology from CSIR-Institute of Genomics and Integrative Biology, New Delhi, India, where she studied liver regeneration and identified small molecules that can protect against drug-induced liverinjury using transgenic zebrafishmodels. She also has experience studying ageing mechanisms in C. elegansin her pre PhDwork. Over the course of her career, she has led multiple cross-disciplinary research projects, resulting in peer-reviewed publications and awards, including the HiRM Precision RNA Medicine Core Pilot Grant, best poster and oral presentation, and the Inclusivity Awardat RNATx 2024 for her advocacy of diversity in RNA science. Beyond the bench, she serveson the Executive Board of the BIDMC Post doctoral Association, co-leading efforts in mentorship, professional development, and career advancement for early-career scientists. Her long-term goal is to bridge basic science and clinical applications to develop innovative therapies for liver and metabolic diseases.

Dr. Howard Y. Chang is responsible for leading all aspects of discovery research at Amgen. Prior to joining Amgen, Dr. Chang led a research laboratory at Stanford University focused on deciphering regulatory information in the human genome for disease diagnosis and therapy. A physician-scientist and board-certified dermatologist, he served as Professor of Dermatology, Genetics, and Pathology at Stanford and Investigator of the Howard Hughes Medical Institute.

Dr. Chang is the winner of the Albany Prize, Lurie Prize in Biomedical Sciences, and NAS Award in Molecular Biology for discoveries of regulatory RNAs. He is an elected member of the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences. He is a serial entrepreneur having founded five biotech companies.

Dr. Chang holds a M.D. from Harvard Medical School, a Ph.D. in Biology from MIT, and an A.B. in Biochemical Sciences from Harvard University.

Eric Minikel has a personal mission: in 2010, his wife Sonia Vallabh watched her 52 year old mother die of a rapid, mysterious, undiagnosed neurodegenerative disease.One year later, Sonia learned that her mother's disease had been genetic prion disease, and that she herself had inherited the causal mutation, placing her at >90% lifetime risk of developing the same incurable disease. With no prior training in biology, Sonia and Eric retainedas scientists and devoted their lives to searching for a treatment or cure for her disease. They earned their PhDs in Biological and Biomedical Sciences from Harvard Medical School in 2019 and now run a 14-person lab together. Eric's prion disease research spans therapeutic discovery, preclinical development, and clinical biomarker and natural history research. Eric's work on antisense oligonucleotides in prion-infected mice led to the current Phase I clinical trialof ION717 in prion disease patients. More recently he has contributed to the preclinical development of divalent siRNA, zinc finger repressors, the epigenetic editor CHARM, and baseediting therapies for prion disease.

Jon is detail-oriented cell biologist/ biochemist with 15 years experience in an academic setting. Well versed in characterization of transcriptional and translational regulation in a variety of systems including metabolic tissues and cancer using in vitro assays, cell culture, and animal models with a track record of successful publications. His recent work has included assay development and testing of novel compounds (PROTACs, stapled peptides, and small molecules) targeting cancer vulnerabilities in cell-based assay systems as well as protein engineering of novel regulatory domains.

Chunyang leads platform development and target discovery to advance next-generation siRNA therapeutics acrossmultiple disease areas. Prior to joining Sanegene, Dr. Zhang began her industry career at Dicerna Pharmaceuticals (now part of Novo Nordisk), following a postdoctoral fellowship at Harvard Medical School/Boston Children’s Hospital. With over eight years of experience in genetic medicine and oligonucleotide drug discovery, Dr. Zhang has played a pivotal role in advancing Sanegene’s pipeline. Her work hascontributed to the development of four clinical-stage assets.

In 2003, Dr. Manoharan was the first chemist hired at Alnylam and built the Drug Discovery team at Alnylam. He and his team pioneered the discovery and development of the chemical modifications that make RNA interference-based human therapeutics possible. This work led to ONPATTRO (patisiran), the first RNAi therapeutic approved by FDA in 2018 for treating TTR amyloidosis mediated polyneuropathy. Dr. Manoharan has had a distinguished career as a world-leading chemist in the areas of oligonucleotide chemical modifications, conjugation chemistry, and delivery platforms (lipid nanoparticles, polymer conjugates, and complex-forming strategies).

Dr. Manoharan and his research group designed, synthesized and demonstrated for the first time the human therapeutic applications of GalNAc-conjugated oligonucleotides at Alnylam, a platform that has revolutionized the RNA therapeutics field with several compounds presently in the advanced clinical trials. The very first GalNAc-siRNA conjugate among them, GIVLAARI (givosiran), for the treatment of acute hepatic porphyria (AHP) has been approved by FDA very recently (November 2019). He is an author of more than 215 publications (nearly 44,500 Google Scholar citations with an h-index of 97 and an i10-index of 375) and over 400 abstracts, as well as an inventor of over 240 issued U.S. patents.

Prior to Alnylam, Dr. Manoharan worked at Ionis (formerly Isis) Pharmaceuticals (1990-2003; Carbohydrate modifications like 2’-O-MOE and Conjugates) and LifeCodes Corporation (1988-1990) in the field of antisense oligonucleotide therapeutics.